Clinical Characteristics and Discharge Assessment of Patients From Palliative Care
Clinical Characteristics and Discharge Assessment of Patients in a Recent Founded Palliative Care Unit
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Adult patients admitted to the Diskapi Yildirim Beyazit Teaching and Research Hospitals Palliative Care Unit between August 2018 and September 2020 and discharged to their home will be retrospectively evaluated.
Patient's age, gender, diagnosis, conditions/comorbidities, Karnofsky Performance Scale, discharge status (death, intensive care unit or at home), gastrostomy status, presence of tracheostomy and/or mechanical ventilation, nutritional status (total parenteral nutrition or enteral nutrition), pressure ulcers, the lowest and highest recorded hemoglobin concentration, white blood cell count and serum sodium concentration and the education level of the patient and the caregiver will be recorded. Patients will be grouped according to length of stay (LOS) as Group 1: discharged in equal or less than 21 days or Group 2: Prolonged discharged in longer than 21 days and analysed accordingly
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Ankara, Turkey
- Diskapi Yildirim Beyazit Teaching and Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
• Adult patients admitted to the palliative care unit
Exclusion Criteria:
• Patients not consenting to participate the study
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Group 1
Discharged from palliative care unit in equal or less than 21 days
|
Discharged from palliative care unit in equal less than 21 days
|
|
Group 2: Prolonged discharged in longer than 21 days
Discharged from palliative care unit in longer than 21 days
|
Discharged from palliative care unit in longer than 21 days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Length of stay
Time Frame: 24 hours after discharge
|
Length of stay will be determined after discharge
|
24 hours after discharge
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Gulten Utebey, Dr, Ministry of Health
Publications and helpful links
General Publications
- Gomes B, Higginson IJ. Where people die (1974--2030): past trends, future projections and implications for care. Palliat Med. 2008 Jan;22(1):33-41. doi: 10.1177/0269216307084606.
- Lau F, Downing GM, Lesperance M, Shaw J, Kuziemsky C. Use of Palliative Performance Scale in end-of-life prognostication. J Palliat Med. 2006 Oct;9(5):1066-75. doi: 10.1089/jpm.2006.9.1066.
- Kelly A, Conell-Price J, Covinsky K, Cenzer IS, Chang A, Boscardin WJ, Smith AK. Length of stay for older adults residing in nursing homes at the end of life. J Am Geriatr Soc. 2010 Sep;58(9):1701-6. doi: 10.1111/j.1532-5415.2010.03005.x. Epub 2010 Aug 24.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Palliative-Discharge
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.